TITLE:
Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes
AUTHORS:
Yoshio Mizuno, Hiromi Fuchikami, Naoko Takeda, Junichi Yamada, Yuko Inoue, Hiroshi Seto, Kazuhiko Sato
KEYWORDS:
Breast Cancer, Oncotype DX, Ki-67, Standardized Assessment
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.3,
March
22,
2016
ABSTRACT: Background: At the 13th St Gallen International Breast Cancer Conference in
2013, a new definition of luminal A-like and luminal B-like breast cancer was proposed,
involving the expression of estrogen receptor (ER), progesterone receptor (PgR),
and Ki-67. We examined the rate of concordance between the risk groups using the
Oncotype DX recurrence score (RS) and the previous and newly proposed luminal subtypes
with the standardized Ki-67 assessment. Method: The relationship between a previously
and newly proposed, immunohistochemically defined luminal A and B subtype with the
Oncotype DX RS of 41 cases of T1-2 N0-1 M0 (ER positive, HER2 negative) breast cancer
was assessed. We first classified the patients into the previously defined luminal
A and B subtypes, according to the level of Ki-67 as either “low” (